Found: 5
Select item for more details and to access through your institution.
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes ( EDITION 4).
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 1, p. 121, doi. 10.1111/dom.13048
- By:
- Publication type:
- Article
Romosozumab and antiresorptive treatment: the importance of treatment sequence.
- Published in:
- Osteoporosis International, 2022, v. 33, n. 6, p. 1243, doi. 10.1007/s00198-021-06174-0
- By:
- Publication type:
- Article
Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density.
- Published in:
- Journal of Bone & Mineral Research, 2022, v. 37, n. 2, p. 256, doi. 10.1002/jbmr.4465
- By:
- Publication type:
- Article
T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
- Published in:
- Journal of Bone & Mineral Research, 2020, v. 35, n. 7, p. 1333, doi. 10.1002/jbmr.3996
- By:
- Publication type:
- Article
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
- Published in:
- 2015
- By:
- Publication type:
- journal article